The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended.
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1183
Email enquiries
If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 24 August 2022 | Discontinued. The company have informed us that they are no longer seeking regulatory approval in this indication. Therefore the appraisal is suspended. |
| 27 July 2017 | Suspended. Company has advised that they will not be pursuing a licensing application for bevacizumab from the European Medicines Authority for this indication at this time. |
| 27 July 2017 | Note added to the project documents |
| 22 July 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual